A real-world evidence substrate, signed at the source.
Longitudinal complex-patient records, IRB-mediated cohort access, and a capsule chain that lets your regulatory and your commercial teams cite the same data.
RWE that survives the FDA review.
The hardest part of real-world evidence is provenance. A cohort without a chain of custody from raw record to study output is a cohort that loses arguments. Lucy's substrate signs every ingestion, every transformation, and every cohort assembly so the regulatory submission can trace back to the source for any claim made on the dataset.
Cohort queries against longitudinal complex-patient records.
For each program: an IRB-mediated cohort assembly against the protocol's inclusion criteria. Lucy returns matched patients with signed records, surfaces the eligibility-defining literature already cited in the chart, and flags the candidates whose consent path is shortest.
For commercial teams: market-shaping cohort insights returned as signed reports rather than slide decks, so the asset-team narrative is anchored in verifiable evidence.
Provenance from raw record to study output.
- IRB-mediated cohort access with patient consent on the chain.
- De-identified data products signed at extraction.
- Master service agreement that survives an FDA real-world evidence audit.
- Trial-matching feeds delivered into your enrollment tooling.
A specific offer
We will run a sample cohort query against one of your active trial protocols, IRB-mediated, returned with a signed provenance report in two weeks.